Status:
COMPLETED
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
Lead Sponsor:
Novartis
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated ...
Eligibility Criteria
Inclusion
- Patients who need scheduled minor ambulatory arthroscopic knee surgery.
Exclusion
- Patients with any surgical or medical conditions which could place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00333567
Start Date
August 1 2006
Last Update
December 13 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Nuremberg, Germany